Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events). Alkeus acquisition consideration: $270M cash plus $180M Tarsus stock valued at $61.38 per share.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Alkeus acquisition consideration: $270M cash plus $180M Tarsus stock valued at $61.38 per share
- Additional payments: up to $350M tied to U.S. regulatory approval and first commercial sale
- Ongoing seller economics: low-to-mid single-digit percentage royalties on worldwide gildeuretinol sales
- Closing expected in 2026, subject to conditions including Hart-Scott-Rodino antitrust clearance
- Stock consideration subject to resale registration rights and a two-month lock-up, with volume limits for certain holders beyond three months
Item 3.02 · Unregistered Sales of Equity Securities
- Tarsus plans private-placement issuance of upfront and potential contingent stock consideration to Alkeus stockholders
- Securities offered only to accredited investors under Securities Act Section 4(a)(2) and Regulation D exemptions
- Transaction may create dilution for existing Tarsus shareholders through stock-based acquisition consideration
- Contingent stock consideration remains dependent on specified future conditions recognized in the transaction terms
Item 8.01 · Other Events
- August 6, 2026 press release announces a Merger Agreement, with transaction details in Exhibit 99.1
- Acquisition outcome remains subject to closing, creating execution and transaction-completion risk
- Potential investor impacts include strategic benefits, milestone payments, royalty payments, and resale registration timing
- Forward-looking statements remain subject to SEC-filed risk factors and may differ materially from expectations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.